Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Gabriella
Gabriella Aviello, Naples IT
| Patent application number | Description | Published |
|---|---|---|
| 20130059018 | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER - This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon. | 03-07-2013 |
Gabriella Borionetti, Novara IT
| Patent application number | Description | Published |
|---|---|---|
| 20090130824 | ARSENIC AND PHOSPHORUS DOPED SILICON WAFER SUBSTRATES HAVING INTRINSIC GETTERING - A process for the preparation of low resistivity arsenic or phosphorous doped (N+/N++) silicon wafers which, during the heat treatment cycles of essentially any arbitrary electronic device manufacturing process, reliably form oxygen precipitates. | 05-21-2009 |
Gabriella Brolén, Gothenburg SE
| Patent application number | Description | Published |
|---|---|---|
| 20100190202 | NOVEL POPULATION OF HEPATOCYTES DERIVED VIA DEFINITIVE ENDODERM (DE-HEP) FROM HUMAN BLASTOCYSTS STEM CELLS - The present disclosure relates to a novel hepatocyte-like cell progenitor and/or a novel hepatocyte-like cell derived via definitive endoderm from human blastocyst-derived stem (hBS) cells, to a method for the preparation of such cells and to the potential use of such cells in, e.g., pharmaceutical drug discovery and development, toxicity testing, cell therapy and medical treatment. In particular is presented a definitive endoderm derived hepatocyte-like cell with important liver-expressed marker genes and important metabolizing enzymes, as well as drug transporters. | 07-29-2010 |
Gabriella Brolén, Gothenburg SE
| Patent application number | Description | Published |
|---|---|---|
| 20090123432 | Novel population of hepatocytes derived via definitive endoderm (DE-hep) from human blastocysts derived stem cells - The present invention relates to a novel hepatocyte-like cell progenitor and/or a novel hepatocyte-like cell derived via definitive endoderm from human blastocyst-derived stem (hBS) cells, to a method for the preparation of such cells and to the potential use of such cells in e.g. pharmaceutical drug discovery and development, toxicity testing, cell therapy and medical treatment. | 05-14-2009 |
| 20100190202 | NOVEL POPULATION OF HEPATOCYTES DERIVED VIA DEFINITIVE ENDODERM (DE-HEP) FROM HUMAN BLASTOCYSTS STEM CELLS - The present disclosure relates to a novel hepatocyte-like cell progenitor and/or a novel hepatocyte-like cell derived via definitive endoderm from human blastocyst-derived stem (hBS) cells, to a method for the preparation of such cells and to the potential use of such cells in, e.g., pharmaceutical drug discovery and development, toxicity testing, cell therapy and medical treatment. In particular is presented a definitive endoderm derived hepatocyte-like cell with important liver-expressed marker genes and important metabolizing enzymes, as well as drug transporters. | 07-29-2010 |
Gabriella Campadelli, Bologna IT
| Patent application number | Description | Published |
|---|---|---|
| 20110318268 | HERPES SIMPLEX VIRUS (HSV) WITH MODIFIED TROPISM, USES AND PROCESS OF PREPARATION THEREOF - A modified Herpes Simplex Virus (HSV), which has a portion of gD (glycoprotein D) of the glycoproteic envelope deleted and a heterologous single chain antibody inserted in place of such deleted portion; the modified HSV is capable of infecting cells through receptor HER2/ErbB2 but not through receptors HVEM/HveA and nectin1/HveC; uses of the modified HSV and a process of the preparation thereof are also disclosed. | 12-29-2011 |
Gabriella Carignano, Arese (mi) IT
| Patent application number | Description | Published |
|---|---|---|
| 20100187469 | Heat transfer fluid - The invention pertains to a heat transfer composition comprising: at least one fluorinated ether fluid free from functional groups (fluid (H)); from 0.01 to 5% wt with respect to fluid (H) of at least one solid nano-sized additive chosen among metal, metal oxide or carbonaceous material particles, having an average particle size of less than 2 000 nm (additive (N)); and from 0.1 to 10% wt with respect to fluid (H) of at least one functional (per)fluoropolyether comprising recurring units (R1), said recurring units comprising at least one ether linkage in the main chain and at least one fluorine atom (fluoropolyoxyalkene chain) and comprising at least one functional group (functional PFPE (F)). | 07-29-2010 |
Gabriella Cincotti, Tokyo JP
| Patent application number | Description | Published |
|---|---|---|
| 20100196005 | Optical Multiport Spectral Phase Encoder - Data security of a multi-dimensional code system is increased. An optical device is provided with a single input port; a splitter splitting an input light from the input port into a plurality of lights; a plurality of phase shifters each shifting one of the lights split by the splitter; a multi-port encoder/decoder inputting the lights whose phases are shifted by the phase shifters and generating spectral encoded codes; and a plurality of output ports outputting the spectral encoded codes generated by the multi-port encoder/decoder. | 08-05-2010 |
| 20110013909 | Optical Code Division Multiplexing Access System - Problem An object of the present invention is to provide an optical code division multiple access system which is used by many people. | 01-20-2011 |
Gabriella Convertino, Francavilla Fontana (brindisi) IT
| Patent application number | Description | Published |
|---|---|---|
| 20090310578 | METHOD AND SYSTEM FOR ENABLING MULTI-CHANNEL DIRECT LINK CONNECTION IN A COMMUNICATION NETWORK, RELATED NETWORK AND COMPUTER PROGRAM PRODUCT - A wireless communication network includes an access point and a plurality of stations. The access point sends towards the stations periodic information arranged in time frames or beacon intervals. The stations in the network are configured to in a first mode through the access point, and in a second mode directly with each other. The time frames are partitioned into a first time interval wherein the stations communicate in the first mode over a first channel; a second time interval wherein the stations communicate in the second mode over a second channel, and a third time interval wherein the stations communicate in either of the first or the second mode. | 12-17-2009 |
| 20120189063 | METHOD FOR ENCODING SIGNALS, RELATED SYSTEMS AND PROGRAM PRODUCT THEREFOR - A method for encoding video signals subjects the signals to unbalanced multiple description coding. The unbalanced multiple description coding codes a video signal in a first high resolution packet and a second low resolution packet and represents, respectively a first high resolution description and a second low resolution description. The unbalanced multiple description coding step includes using different intra refresh periods for the first and second high resolution descriptions, with an intra refresh period for the second low resolution description shorter than the intra refresh period of the first high resolution description. | 07-26-2012 |
Gabriella Convertino, Francavilla Fontana IT
| Patent application number | Description | Published |
|---|---|---|
| 20100122127 | METHOD AND SYSTEM FOR CORRECTING BURST ERRORS IN COMMUNICATIONS NETWORKS, RELATED NETWORK AND COMPUTER-PROGRAM PRODUCT - The errors that may occur in transmitted numerical data on a channel affected by burst errors, are corrected via the operations of: ordering the numerical data in blocks each comprising a definite number of data packets; generating for each block a respective set of error-correction packets comprising a respective number of correction packets, the respective number identifying a level of redundancy for correcting the errors; and modifying dynamically the level of redundancy according to the characteristics of the bursts and of the correct-reception intervals between two bursts. Preferential application is on local networks, such as W-LANs for use in the domestic environments. | 05-13-2010 |
Gabriella Dessole, Rome IT
| Patent application number | Description | Published |
|---|---|---|
| 20100210581 | Nucleoside Derivatives as Inhibitors of Viral Polymerases - A class of nucleoside derivatives of formula (I), as defined herein, that are useful as inhibitors of RNA-dependent RNA viral replication and in particular HCV replication, are provided. Also provided are processes for the synthesis and use of such compounds for treating or preventing HCV infection. | 08-19-2010 |
| 20100261709 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS - The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinaldamage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment. | 10-14-2010 |
| 20110183974 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS - The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of the Sonic Hedgehog pathway, in particular Smo antagonists. Thus the compounds of this invention are useful for the treatment of diseases associated with abnormal hedgehog pathway activation, including cancer, for example basal cell carcinoma, medulloblastoma, prostate, pancreatic, breast, colon, bone and small cell lung cancers, and cancers of the upper GI tract. | 07-28-2011 |
Gabriella Kazai, Bishops Stortford GB
| Patent application number | Description | Published |
|---|---|---|
| 20100146015 | Rich-Context Tagging of Resources - Tagging of resources in order to associate them is described. In an embodiment it is possible to assign tags to resources or switch between resources with different tags, in the context of current work being undertaken by a user. For example, from a single application window that is currently used, a user is able to switch to other resources by tag in an embodiment. Different embodiments illustrate how tags may have multiple purposes and those purposes may evolve thus enabling associated resources to be exposed in different ways. In some embodiments rich metadata about tag usage and/or the use of resource associated with a tag is stored and used to provide additional functionality. Examples are described in which persistence of resources associated with tags is provided and may involve representation of resources such as by duplication of files or by creating alternative representations of resources. | 06-10-2010 |
Gabriella Marfe', Rome IT
| Patent application number | Description | Published |
|---|---|---|
| 20080249080 | Benzodiazepine Derivatives and Uses Thereof on Medical Field - The invention concerns benzodiazepine derivatives of formula | 10-09-2008 |
Gabriella Metraux, Hillsboro, OR US
| Patent application number | Description | Published |
|---|---|---|
| 20100133489 | Photoinduced phase separation of gold in two-component nanoparticles to form nanoprisms - Nanoprisms containing silver and gold are disclosed. The nanoprisms exhibit the properties of pure silver nanoprisms, but are less susceptible to silver modification or reaction by a surrounding environment than pure silver nanoprisms due to the presence of the gold. The gold surface of the nanoprisms can be further modified, using known gold-modification techniques. | 06-03-2010 |
Gabriella Metraux, Evanston, IL US
| Patent application number | Description | Published |
|---|---|---|
| 20080295646 | Method of Making Metal Nanoprisms Having a Predetermined Thickness - A method of preparing metal nanoprisms having a unimodal size distribution and a predetermined thickness. The present method also allows control over nanoprism edge length. | 12-04-2008 |
Gabriella Miklóssy, Debrecen HU
| Patent application number | Description | Published |
|---|---|---|
| 20110028397 | Use of Urokinase Type Plasminogen Activator Inhibitors for the Treatment of Corneal Disorders - The invention concerns the use of inhibitors of the urokinase type of plasminogen activator (uPA) appearing in the anterior segment of the eye, for the treatment and prevention of corneal ulcers and other disorders. The invention further concerns pharmaceutical compositions, comprising inhibitors of uPA, preferably eye drops and eye ointments. The pharmaceutical compositions according to the invention preferably comprise PAI-2 protein or a derivative thereof retaining uPA-inhibiting capacity, or a tripeptide aldehyde inhibitor, preferably the D-Phe-Pro-Arg-aldehyde (Ald-1). The PAI-2 protein, used according to the invention, is preferably produced through bacterial expression, as a fusion protein. | 02-03-2011 |
Gabriella Miklóssy, Debrecen HU
| Patent application number | Description | Published |
|---|---|---|
| 20110028397 | Use of Urokinase Type Plasminogen Activator Inhibitors for the Treatment of Corneal Disorders - The invention concerns the use of inhibitors of the urokinase type of plasminogen activator (uPA) appearing in the anterior segment of the eye, for the treatment and prevention of corneal ulcers and other disorders. The invention further concerns pharmaceutical compositions, comprising inhibitors of uPA, preferably eye drops and eye ointments. The pharmaceutical compositions according to the invention preferably comprise PAI-2 protein or a derivative thereof retaining uPA-inhibiting capacity, or a tripeptide aldehyde inhibitor, preferably the D-Phe-Pro-Arg-aldehyde (Ald-1). The PAI-2 protein, used according to the invention, is preferably produced through bacterial expression, as a fusion protein. | 02-03-2011 |
Gabriella Minchlotti, Napoli IT
| Patent application number | Description | Published |
|---|---|---|
| 20110028401 | CRIPTO BLOCKING MOLECULES AND THERAPEUTIC USES THEREOF - The present invention concerns a monomeric or multimeric tripeptide molecule able of inhibiting Cripto signalling in embryonic stem cells, thereby enhancing dopamine specification and differentiation, after transplantation in animal models of Parkinson's disease, as well as reducing tumor formation, and uses thereof. | 02-03-2011 |
Gabriella Pezzoni, Bresso IT
| Patent application number | Description | Published |
|---|---|---|
| 20100292322 | Bis-Platinum Complexes With Antitumor Activity - A compound of general formula (I): in which: R is selected from the group consisting of (C | 11-18-2010 |
Gabriella Pezzoni, Milan IT
| Patent application number | Description | Published |
|---|---|---|
| 20130018096 | PLATINUM COMPLEX WITH ANTITUMOR ACTIVITYAANM De Munari; SergioAACI MilanAACO ITAAGP De Munari; Sergio Milan ITAANM Di Giovine; StefanoAACI MilanAACO ITAAGP Di Giovine; Stefano Milan ITAANM Grugni; MarioAACI MilanAACO ITAAGP Grugni; Mario Milan ITAANM Nicoli; PaolaAACI MilanAACO ITAAGP Nicoli; Paola Milan ITAANM Paganelli; AlessandroAACI MilanAACO ITAAGP Paganelli; Alessandro Milan ITAANM Pardi; GianlucaAACI San Giuliano Terme (Pisa)AACO ITAAGP Pardi; Gianluca San Giuliano Terme (Pisa) ITAANM Pezzoni; GabriellaAACI MilanAACO ITAAGP Pezzoni; Gabriella Milan IT - The present invention relates to the antitumor compound of formula (I) a process for its preparation and pharmaceutical compositions containing it. | 01-17-2013 |
Gabriella Singrossi, Milan IT
| Patent application number | Description | Published |
|---|---|---|
| 20110245221 | ARYL ISOXAZOLE COMPOUNDS WITH ANTITUMOURAL ACTIVITIES - The present invention relates to formula I compounds having antitumoural activities through, as one possible biological target, the molecular chaperone heat shock protein 90 (Hsp90) inhibition. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of Hsp90 is responsive, and the pharmaceutical compositions containing such compounds. | 10-06-2011 |
| 20120093809 | USE OF ALKANOYL L-CARNITINE IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF NEOPLASMS - The present invention relates to the use of an alkanoyl L-carnitine selected from the group consisting of acetyl, propionyl, valeryl, isovaleryl and butirryl L-carnitine; in combination with one or more chemotherapeutic agent selected from the group consisting of: a camptothecin derivative; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a topoisomerase inhibitor; a VEGF inhibitor; a tyrosine kinase inhibitor; an EGFR kinase inhibitor; an mTOR kinase inhibitor; an insulin-like growth factor I inhibitor; a Raf kinase inhibitor; a monoclonal antibody; a proteasome inhibitor; a HDAC inhibitor; toxins; and imides; for the treatment of neoplasms. | 04-19-2012 |
| 20120208883 | TREATMENT OF ONCOLOGICAL DISEASES - The present invention relates to the use of acetyl L-carnitine for the preparation of a medicament for the prevention and/or treatment of cancer. Methods of preventing and/or treatment of cancer by administering an effective amount of acetyl L-carnitine to subject in need thereof are also disclosed. | 08-16-2012 |
Gabriella Sozzi US
| Patent application number | Description | Published |
|---|---|---|
| 20120225925 | Micro-RNA Biomarkers and Methods of Using Same - A procedure and an apparatus are described for identifying individuals at risk of pulmonary tumour and/or for diagnosing a pulmonary tumour using the study of levels of expression of miRNA in the blood or another biological fluid. Also described are a method and a compound for reducing or eliminating a risk of pulmonary tumour by rebalancing the miRNAs that are underexpressed or overexpressed. | 09-06-2012 |
Gabriella Traquandi, Milan IT
| Patent application number | Description | Published |
|---|---|---|
| 20090124605 | Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors - Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer. | 05-14-2009 |
| 20100075998 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES - The present invention provides tricyclic indoles and (4,5-dihydro) indoles of the formula (I) or a pharmaceutically acceptable salt thereof: wherein the ring A represents a fused pyrazole, pyridine or pyrimidine, | 03-25-2010 |
| 20110144068 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS - 3,4-diarylpyrazole derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer. | 06-16-2011 |
| 20130053419 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS - Compounds which are sulfonamido 3,4-diarylpyrazole derivatives, or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders; also disclosed is their use as prodrugs. | 02-28-2013 |
Gabriella Trespalacios, Coto De Caza, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20100263102 | GARMENT PROTECTOR - A garment protector is configured to absorb moisture and to thereby preserve a garment of a user. The garment protector can have a pad attached to the garment. The pad can absorb moisture and reduce or prevent moisture from staining the garment. The garment protector can have multiple layers to perform these functions. The garment protector can have one or more application channels. The application channel can span a seam and the associated cross-stitching of a garment so as not to add bulk at the seam that a pad would if over the seam. | 10-21-2010 |
Gabriella Zupi, Roma IT
| Patent application number | Description | Published |
|---|---|---|
| 20110142827 | TREATMENT OF CANCER WITH A COMBINATION OF AN AGENT THAT PERTURBS THE EGF SIGNALING PATHWAY AND AN OLIGONUCLEOTIDE THAT REDUCES CLUSTERIN LEVELS - Agents that perturb the EGF signaling pathway and that are known to be useful in the treatment of cancer are found also to result in increased expression of the protein clusterin. Since clusterin can provide protection against apoptosis, this secondary effect detracts from the efficacy of the therapeutic agent. This is overcome using a combination of an agent that has known therapeutic efficacy against the cancer to be treated by perturbation of the EGF signaling pathway and that stimulates expression of clusterin as a secondary effect, and an oligonucleotide that is effective to reduce the amount of clusterin in cancer cells. For example, the agent may be an antibody specific for HER-2, a small molecule inhibitor of HER-2, an antisense oligonucleotide specific for HER-2, or a peptide agent capable of interfering with HER-2 protein. The oligonucleotide may be an antisense oligonucleotide or an RNAi oligonucleotide. | 06-16-2011 |